A carregar...
Phase I/II Study of Single-Agent Bortezomib for the Treatment of Patients with Myelofibrosis. Clinical and Biological Effects of Proteasome Inhibition
A phase I/II trial was undertaken to determine maximum tolerated dose (MTD), toxicity, clinical efficacy and biological activity of bortezomib in patients with advanced stage primary or post-polycythemia vera/post-essential thrombocythemia myelofibrosis (MF). Bortezomib (0.8, 1.0, or 1.3 mg/m(2)) wa...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2947025/ https://ncbi.nlm.nih.gov/pubmed/20540156 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21754 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|